“`html
Mantle Cell Lymphoma Treatment Patterns and Efficacy
Key Findings:
- 536 patients with mantle cell lymphoma (MCL) were studied
- Front-line treatments included high-dose cytarabine, bendamustine, and anthracyclines
- Median progression-free survival (PFS) for all patients was 45 months
- Second-line treatments varied, with bendamustine-based regimen being the most common
- Median second-line PFS was little over 1 year
Practical Solutions and Value:
- Understanding treatment patterns and efficacy in MCL is crucial for optimizing patient care
- Front-line treatments showed promising median PFS of over 3.5 years
- Identification of superior second-line treatment strategies can help improve outcomes for MCL patients
For the full clinical trial report, please visit: Clinical Trial Report
“`
